NCT05103293View on ClinicalTrials.gov

PTC Guiding Neoadjuvant Treatment in Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

December 10, 2023

Study Completion Date

December 10, 2023

Conditions
Pathological Conditions, Signs and Symptoms
Interventions
DIAGNOSTIC_TEST

patient-derived tumor-like cell clusters drug sensitivity test

Intervention Description：Neoadjuvant therapy regimen of patients in the PTC group is guided by PTC drug sensitivity results. After operation, adjuvant targeted therapy for pCR patients is based on original treatment, adjuvant targeted therapy for non-pCR patients is based on a secondary PTC drug sensitivity results.

Trial Locations (1)

310000

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER

NCT05103293 - PTC Guiding Neoadjuvant Treatment in Breast Cancer | Biotech Hunter | Biotech Hunter